Treatment of COPD Groups GOLD A and B with Inhaled Corticosteroids in the COSYCONET Cohort – Determinants and Consequences

References

• Halpin DMG, de Jong HJI, Carter V, Skinner D, Price D. Distribution, Temporal Stability and Appropriateness of Therapy of Patients With COPD in the UK in Relation to GOLD 2019. E Clin Med. 2019;14:32–41. doi:10.1016/j.eclinm.2019.07.003
   Web of Science ®Google Scholar
• White P, Thornton H, Pinnock H, Georgopoulou S, Booth HP. Overtreatment of COPD with inhaled corticosteroids–implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221. doi:10.1371/journal.pone.0075221
   PubMed Web of Science ®Google Scholar
• Jochmann A, Scherr A, Jochmann DC, et al. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly. 2012;142:w13567.
   PubMed Web of Science ®Google Scholar
• Roche N, Jebrak G, Caillaud D, et al. Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. Eur Respir J. 2015;45(1):260–262. doi:10.1183/09031936.00131614
   PubMed Web of Science ®Google Scholar
• Roche N, Lepage T, Bourcereau J, Terrioux P. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2001;18(6):903–908. doi:10.1183/09031936.01.00213701
   PubMed Web of Science ®Google Scholar
• Tsiligianni I, Kampouraki M, Ierodiakonou D, Poulonirakis I, Papadokostakis P. COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study. Int J Chron Obstruct Pulmon Dis. 2019;14:547–556. doi:10.2147/COPD.S185362
   PubMed Web of Science ®Google Scholar
• Geraets I, Schermer T, Kocks JWH, Akkermans R, Bischoff E, van den Bemt L. Primary care cohort study in the sequence of diagnosing chronic respiratory diseases and prescribing inhaled corticosteroids. NPJ Prim Care Respir Med. 2018;28(1):37. doi:10.1038/s41533-018-0106-6
   PubMedGoogle Scholar
• Urwyler P, Abu Hussein N, Bridevaux PO, et al. Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. Multidiscip Respir Med. 2019;14(1):7. doi:10.1186/s40248-019-0168-5
   PubMedGoogle Scholar
• Graf J, Jorres RA, Lucke T. An analysis of guideline-adherent prescribing in a large national cohort (COSYCONET). Deutsches Ärzteblatt. 2018. 115(37):599.
   Google Scholar
• Yang IA, Fong KM, Sim EH, Black PN, Lasserson TJ, Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2007;2:CD002991. doi:10.1002/14651858.CD002991.pub2
   PubMed Web of Science ®Google Scholar
• Price DB, Voorham J, Brusselle G, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. NPJ Prim Care Respir Med. 2019;29(1):38. doi:10.1038/s41533-019-0150-x
   PubMedGoogle Scholar
• Fens T, van der Pol S, Kocks JWH, Postma MJ, van Boven JFM. Economic impact of reducing inappropriate inhaled corticosteroids use in patients with chronic obstructive pulmonary disease: ISPOR’s guidance on budget impact in practice. Value Health. 2019;22(10):1092–1101. doi:10.1016/j.jval.2019.05.006
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP
   PubMed Web of Science ®Google Scholar
• Turan O, Yemez B, Itil O. The effects of anxiety and depression symptoms on treatment adherence in COPD patients. Prim Health Care Res Dev. 2014;15(3):244–251. doi:10.1017/S1463423613000169
   PubMed Web of Science ®Google Scholar
• Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev. 2014;23(133):345–349. doi:10.1183/09059180.00007813
   PubMedGoogle Scholar
• Kahnert K, Alter P, Young D, et al. The revised GOLD 2017 COPD categorization in relation to comorbidities. Respir Med. 2018;134:79–85. doi:10.1016/j.rmed.2017.12.003
   PubMed Web of Science ®Google Scholar
• Karch A, Vogelmeier C, Welte T, et al. The German COPD cohort COSYCONET: aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi:10.1016/j.rmed.2016.03.008
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-2017
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Budweiser S, Meyer K, Jorres RA, Heinemann F, Wild PJ, Pfeifer M. Nutritional depletion and its relationship to respiratory impairment in patients with chronic respiratory failure due to COPD or restrictive thoracic diseases. Eur J Clin Nutr. 2008;62(3):436–443. doi:10.1038/sj.ejcn.1602708
   PubMed Web of Science ®Google Scholar
• Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006;9(6):755–762. doi:10.1079/PHN2005898
   PubMed Web of Science ®Google Scholar
• Lucke T, Herrera R, Wacker M, et al. Systematic Analysis of Self-Reported Comorbidities in Large Cohort Studies – A Novel Stepwise Approach by Evaluation of Medication. PLoS One. 2016;11(10):e0163408. doi:10.1371/journal.pone.0163408
   PubMed Web of Science ®Google Scholar
• Criee CP, Baur X, Berdel D, et al. [Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine]. Pneumologie. 2015;69(3):147–164. doi:10.1055/s-0034-1391345
   PubMedGoogle Scholar
• Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J. 2015;45(4):879–905. doi:10.1183/09031936.00009015
   PubMed Web of Science ®Google Scholar
• Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J. 2017;50(3):1700010. doi:10.1183/13993003.00010-2017
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40. doi:10.1183/09041950.005s1693
   PubMedGoogle Scholar
• Byng D, Lutter JI, Wacker ME, et al. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET. Int J Chron Obstruct Pulmon Dis. 2019;14:1423–1439. doi:10.2147/COPD.S201899
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679. doi:10.1002/sim.6607
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic obstructive lung disease. 2021 GOLD reports. Available from: https://goldcopd.org/2021-gold-reports. Accessed April 8, 2021.
   Google Scholar
• Vogelmeier C, Buhl R, Burghuber O, et al. S2k-Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie. 2018;72(4):253–308. doi:10.1055/s-0043-125031
   Google Scholar
• Evidence reviews for the length of corticosteroid use during exacerbationsChronic obstructive pulmonary disease in over 16s: diagnosis and managementEvidence review JNICE Guideline, No. 115NICE Guideline Updates Team (UK).London: National Institute for Health and Care Excellence (UK); 2019. ISBN-13: 978-1-4731-3468-3
   Google Scholar
• Souliotis K, Silva Miguel L, Hillas G, et al. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620926802. doi:10.1177/1753466620926802
   Web of Science ®Google Scholar
• Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45(2):525–537. doi:10.1183/09031936.00128914
   PubMed Web of Science ®Google Scholar
• Latorre M, Novelli F, Vagaggini B, et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS. Pulm Pharmacol Ther. 2015;30:44–50. doi:10.1016/j.pupt.2014.10.006
   PubMed Web of Science ®Google Scholar
• Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. 2020;383(1):35–48. doi:10.1056/NEJMoa1916046
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, Phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758.
   PubMed Web of Science ®Google Scholar
• van den Bemt L, van den Nieuwenhof L, Rutjes A, et al. Pragmatic trial on inhaled corticosteroid withdrawal in patients with COPD in general practice. NPJ Prim Care Respir Med. 2020;30(1):43. doi:10.1038/s41533-020-00198-5
   PubMed Web of Science ®Google Scholar
• Sandek K, Bratel T, Lagerstrand L. Effects on diffusing capacity and ventilation–perfusion relationships of budesonide inhalations for 2 months in chronic obstructive pulmonary disease (COPD). Respir Med. 2001;95(8):676–684. doi:10.1053/rmed.2001.1124
   PubMed Web of Science ®Google Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. [Long-term effect of inhaled budesonide in patients with mild to moderate chronic obstructive lung disease. The Osterbro Study]. Ugeskr Laeger. 2000;162(4):493–497.
   PubMedGoogle Scholar
• Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823. doi:10.1016/S0140-6736(98)10019-3
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340(25):1948–1953. doi:10.1056/NEJM199906243402503
   PubMed Web of Science ®Google Scholar
• Marietta von Siemens S, Alter P, Lutter JI, et al. CAT score single item analysis in patients with COPD: results from COSYCONET. Respir Med. 2019;159(105810):105810. doi:10.1016/j.rmed.2019.105810
   PubMedGoogle Scholar
• Karl FM, Holle R, Bals R, et al. Costs and health-related quality of life in Alpha-1-Antitrypsin Deficient COPD patients. Respir Res. 2017;18(1):60. doi:10.1186/s12931-017-0543-8
   PubMed Web of Science ®Google Scholar
• Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11(Spec Iss):21–30. doi:10.2147/COPD.S85978
   PubMedGoogle Scholar
• Jones PW, Lamarca R, Chuecos F, et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J. 2014;44(5):1156–1165. doi:10.1183/09031936.00038814
   PubMed Web of Science ®Google Scholar
• Shin J, Yoon HY, Lee YM, Ha E, Lee JH. Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study. Sci Rep. 2020;10(1):18973. doi:10.1038/s41598-020-74854-8
   PubMed Web of Science ®Google Scholar
• Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J. 2005;25(4):634–639. doi:10.1183/09031936.05.00079004
   PubMed Web of Science ®Google Scholar